Drug Trial Radar · NCT05875168
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
590
Planned (sponsor's estimate)
Start
Aug 18, 2023
Primary completion
Aug 11, 2028
Study completion Nov 11, 2028
Sponsor
- Lead sponsor
- Daiichi SankyoDaiichi Sankyo (DSNKY)
- Sponsor type
- Industry
- First posted
- May 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety, tolerability, and efficacy of DS-3939a in participants with advanced solid tumors.
Conditions
- Advanced Solid Tumor
- Metastatic Solid Tumor
Interventions
DS-3939aDrug
One IV infusion Q3W on Day 1 of each 21-day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Dose-limiting Toxicities Following Treatment With DS-3939aTime frame: Approximately 3 months after first dosing
- Overall Number of Participants with Treatment-emergent Adverse Events and Serious Adverse Events Following Treatment With DS-3939aTime frame: Up to approximately 31 months
- Number of Participants with Objective Response Rate Following Treatment With DS-3939a (Part 2)Time frame: Up to approximately 31 months
- PSA50 Response Rate Following Treatment with DS-3939a (Part 2; CRPC only)Time frame: Up to approximately 31 months
Locations
61 sites in 8 countries. Site status is shown where the registry gives one.
Florida Cancer Specialists
Sarasota, Florida · Withdrawn
Florida Cancer Specialists
Sarasota, Florida · Recruiting
Piedmont Cancer Institute
Locust Grove, Georgia · Withdrawn
University of Kansas Medical Center
Westwood, Kansas · Recruiting
Henry Ford Health System
Detroit, Michigan · Withdrawn
Astera Cancer Care
East Brunswick, New Jersey · Recruiting
Icahn School of Medicine Mt Sinai
New York, New York · Withdrawn
Oregon Health & Science University
Portland, Oregon · Recruiting
Rhode Island Hospital
Providence, Rhode Island · Recruiting
University of Texas M.D. Anderson Cancer Center
Houston, Texas · Recruiting
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah · Recruiting
Virginia Cancer Specialists
Fairfax, Virginia · Withdrawn
The Medical College of Wisconsin, INC
Milwaukee, Wisconsin · Recruiting
The Medical College of Wisconsin, INC
Milwaukee, Wisconsin · Withdrawn
UZ Leuven
Leuven, Belgium · Recruiting
McGill University Health Center
Montreal, Canada · Withdrawn
Princess Margaret Cancer Center
Toronto, Canada · Recruiting
Beijing Cancer Hospital
Beijing, China · Withdrawn
Jilin Cancer Hospital
Changchun, China · Withdrawn
Hunan Cancer Hospital
Changsha, China · Withdrawn
Sichuan Cancer Hospital
Chengdu, China · Recruiting
Zhejiang Cancer Hospital
Hangzhou, China · Recruiting
Shandong Cancer Hospital
Jinan, China · Recruiting
The First Affiliated Hospital of Nanchang University
Nanchang, China · Recruiting
The Second Peoples Hospital of Neijiang
Neijiang, China · Recruiting
Shanghai East Hospital
Shanghai, China · Recruiting
Tianjin Medical University Cancer Institute & Hospital
Tianjin, China · Withdrawn
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China · Withdrawn
The First Affiliated Hospital of Xiâan Jiaotong University
Xi'an, China · Withdrawn
Xiangyang Central Hospital
Xiangyang, China · Recruiting
Centre Léon Bérard
Lyon, France · Recruiting
Centre Léon Bérard
Lyon, France · Withdrawn
Assistance Publique- de Marseille
Marseille, France · Recruiting
Ico - Site René Gauducheau
Saint-Herblain, France · Recruiting
Chu Strasbourg
Strasbourg, France · Withdrawn
Institut Claudius Regaud
Toulouse, France · Recruiting
Institut Claudius Regaud
Toulouse, France · Recruiting
Institut Gustave Roussy
Villejuif, France · Recruiting
National Cancer Center Hospital
Chūōku, Japan · Recruiting
Kansai Medical University Hospital
Hirakata-shi, Japan · Recruiting
Showing 40 of 61 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.